A recent observation from the CANVAS (Canagliflozin Cardiovascular Assessment Study) study has shown that canagliflozin treatment in T2DM patients with NT-proBNP levels above 125 pg/ml achieved greater absolute risk reductions in event rates compared to those with lower concentrations [18]. This evidence concerns the gene NPPB and type 2 diabetes mellitus.